^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    SET-NUP214 fusion

    i
    Other names: SET, SET Nuclear Proto-Oncogene, Inhibitor Of Granzyme A-Activated DNase, HLA-DR-Associated Protein II, PHAPII, TAF-I, SET Translocation (Myeloid Leukemia-Associated), Protein Phosphatase Type 2A Inhibitor, Phosphatase 2A Inhibitor I2PP2A, Chromatin Remodelling Factor, Protein SET, TAF-IBETA, IPP2A2, Template-Activating Factor-I, Chromatin Remodelling Factor, Inhibitor-2 Of Protein Phosphatase-2A, Template-Activating Factor-I, Template-Activating Factor I, SET Nuclear Oncogene, I2PP2A, MRD58, NUP214, Nucleoporin 214, Nuclear Pore Complex Protein Nup214, CAN Protein, Putative Oncogene, Nucleoporin 214kDa, CAIN, Nucleoporin 214kD (CAIN), 214 KDa Nucleoporin, Nucleoporin Nup214, Protein CAN, IIAE9
    Entrez ID:
    8021; 6418
    Related biomarkers:
    Mutation
    Fusion
    Others
    2ms
    Chidamide maintenance therapy after allo-HSCT in SET-NUP214 fusion positive T-ALL patients: A report of two cases. (PubMed, Transpl Immunol)
    Here we report chidamide maintenance therapy after allo-HSCT in patients with SET-NUP214 fusion positive T-ALL. Both patients improved effectively during follow-up, confirming the efficacy of chidamide in improving the condition of these patients and may provide valuable clinical information for the treatment of this rare and understudied disease.
    Journal
    |
    NUP214 (Nucleoporin 214)
    |
    SET-NUP214 fusion
    |
    Epidaza (chidamide)
    1year
    The outcome of acute leukemia patients with SET-NUP214 fusion after allogeneic stem cell transplantation. (PubMed, Front Oncol)
    The research shows a high incidence of relapse for patients with acute leukemia with the SET-NUP214 fusion gene, even after alloHSCT. More clinical trials or research with larger samples are urgently needed for this group of patients.
    Journal
    |
    NUP214 (Nucleoporin 214)
    |
    SET-NUP214 fusion
    over1year
    Clinical Analysis of SET-NUP214 Fusion Gene Positive Patients with Acute Leukemia (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
    The fusion site of SET-NUP214 fusion gene is relatively fixed in AL patients, often accompanied by extramedullary infiltration. The chemotherapy effect of this disease is poor, and allo-HSCT may improve its prognosis.
    Retrospective data • Journal
    |
    NUP214 (Nucleoporin 214)
    |
    SET-NUP214 fusion
    over1year
    Allogeneic hematopoietic stem cell transplantation in acute leukemia patients with the SET-NUP214 fusion gene: Efficacy and survival analysis (PubMed, Zhonghua Nei Ke Za Zhi)
    Allo-HSCT can improve the prognosis and long-term survival rate of patients with SET-NUP214AL. Disease recurrence is the most important factor affecting long-term survival.
    Journal
    |
    NUP214 (Nucleoporin 214)
    |
    SET-NUP214 fusion
    3years
    Analysis of the clinical characteristics of 24 cases of hematological malignancies with SET-NUP214 fusion gene (PubMed, Zhonghua Xue Ye Xue Za Zhi)
    After HSCT, the 3-year RFS of SET-NUP214(+)T-ALL and SET-NUP214(-)T-ALL was 38.5% and 66.4%, respectively (P=0.028) , and the difference was statistically significant. The SET-NUP214 fusion gene is mainly detected in T cell-derived hematological malignancies, and the prognosis of SET-NUP214 positive T-ALL is relatively poor.
    Clinical • Retrospective data • Journal
    |
    NUP214 (Nucleoporin 214) • CD7 (CD7 Molecule) • CD2 (CD2 Molecule)
    |
    SET-NUP214 fusion • CD7 expression